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Summary
As a result of epidemic levels of obesity and diabetes mel-
litus, nonalcoholic fatty liver disease (NAFLD) and nonal-
coholic steatohepatitis (NASH) will contribute to increases
in the liver-related disease burden in Switzerland.
A Markov model was built to quantify fibrosis progression
among the NAFLD and NASH populations, and predict
disease burden up to 2030. Long-term trending of NAFLD
prevalence was based on changes in the prevalence of
adult obesity. Published estimates and surveillance data
were applied to build and validate the model projections.
The prevalence of NAFLD increased up to 2030 in tandem
with projected increases in adult obesity. By 2030, there
were an estimated 2,234,000 (1,918,000–2,553,000)
NAFLD cases, or 24.3% (20.9–27.8%) of the total Swiss
population (all ages). Increases in NASH cases were rel-
atively greater than NAFLD cases. Incident cases of ad-
vanced liver disease are projected to increase by approx-
imately 40% by 2030, and incident NAFLD liver deaths to
increase from 580 deaths in 2018 to 820 deaths in 2030.
Continued growth in obesity, in combination with an aging
population, will result in increasing number of cases of ad-
vanced liver disease and mortality related to NAFLD and
NASH. Slowing the growth in obesity and metabolic syn-
drome, along with future potential therapies, are required
to reduce liver disease burden.
Keywords: metabolic syndrome, non-alcoholic fatty liver
disease, liver cirrhosis, liver neoplasms, carcinoma, hepa-
tocellular
Introduction
Nonalcoholic fatty liver is increasingly recognised as a
cause of liver disease in Europe, where prevalence of was
estimated at 23.71% (95% confidence interval [CI]
16.12–33.45%) during 2000–2015 [1]. Globally, nonalco-
holic fatty liver disease (NAFLD) now accounts for greater
numbers of advanced liver disease cases, including hepato-
cellular carcinoma (HCC) and liver transplantation [2–5],
with a substantial economic impact [6]. As with other
chronic lifestyle conditions, it is increasing in Switzerland
with the epidemics of obesity [7, 8] and type 2 diabetes
mellitus (DM) [9]. NAFLD is reported to account for in-
creasing numbers of cases of advanced liver disease in Eu-
rope [10], including liver cancer [11]. Morbidity related to
NAFLD and nonalcoholic steatohepatitis (NASH) is like-
ly to increase in the coming decades, especially in coun-
tries with aging populations [12, 13] that experience higher
rates of chronic lifestyle-related conditions. In this analy-
sis, a Markov model was built using data from Switzerland
for obesity and HCC to predict and validate changes in the
burden of NAFLD-related liver disease up to 2030.
NAFLD is characterised by excessive liver fat in the ab-
sence of other causes [14, 15], with overweight/obesity,
DM and metabolic syndrome identified as important risk
factors [14, 16]. In the current analysis, NAFLD cases
were tracked by fibrosis stage and further classified as
NAFL (NAFLD cases with steatosis only) or NASH,
where inflammation can progress to liver fibrosis, and ad-
vanced liver disease and related mortality [17, 18]. In-
creased age, in combination with obesity, DM and meta-
bolic syndrome are reported to be predictive for
progression of disease and cirrhosis [16, 19]. Advanced
liver disease usually occurs after a period of significant fi-
brosis and cirrhosis, whereas HCC often occurs in patients
with NASH-related cirrhosis; however, HCC can occur in
non-cirrhotic NASH patients [20, 21].
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There is currently a pressing need to understand the future
burden of NAFLD-related liver disease. Use of a disease
burden modelling framework allows more efficient distri-
bution of limited resources, while assisting in the develop-
ment of strategies to mitigate further growth in morbidity
and mortality.
Recent reports analysed the disease and cost burden related
to NASH [1, 22, 23] based on existing literature. In addi-
tion, a recent dynamic model of NAFLD progression over-
comes several limitations in data availability [24, 25]. In
this analysis, we report the development of such a model
for Switzerland, based on the trend for adult obesity in the
country [7, 8].
Methods
Model
To estimate changes over time in NAFLD disease burden,
a Markov model was constructed. The model calculated
the NAFLD population by fibrosis stage and NASH status
(NAFL or NASH). Progression of disease through fibrosis
and liver disease stages (fig. 1) was calculated with adjust-
ment for all-cause mortality, including liver-related mor-
tality (supplementary table S1 in appendix 1), background
mortality (table S2) and excess cardiovascular disease
(CVD) mortality (table S3), with fibrosis progression rates
(table S1) back-calculated using surveillance data [24].
The total population by age group and gender was tracked
over time, with new NAFLD cases entering the model
based on adult obesity prevalence trends in Switzerland.
Fibrosis transition rates were varied by gender (males ex-
periencing faster progression), with rates that also in-
creased with advanced age (table S1). Results from the
analysis were compared with estimates for the incidence of
liver cancer, after accounting for liver cancer under-report-
ing, cancer morphology (HCC), and the estimated aetiolo-
gy of incident HCC cases (NAFLD, viral hepatitis, etc.)
In addition, model results were compared with studies in
European populations that estimated the prevalence of ad-
vanced fibrosis and incidence of liver cancer attributable
to NAFLD [11, 13, 26, 27]. Progression rates to end-stage
disease and liver-related death were based on reported es-
timates [24] (table S1). Indexed articles and non-indexed
sources including national data reports were utilised to
identify reported estimates of NAFLD or NASH preva-
lence, including reports of advanced liver disease attribut-
able to NAFLD or NASH. Estimates for adult prevalence
of obesity (body mass index [BMI] ≥30 kg/m2) and DM at
the national level were included in the analysis, where in-
creases in NAFLD prevalence were assumed to follow the
change in adult obesity over time [28]. In addition to a lit-
erature review, a Delphi process was used to incorporate
expert input based on interviews to identify key model in-
puts and review outputs against available estimates of dis-
ease burden, as shown in figure S1 in appendix 1.
Population and mortality
The total population of Switzerland was organised by year
(1950–2030), gender, and 5-year age groups based on his-
torical estimates and projections from the Swiss Federal
Statistical Office ‘Reference’ scenario A-00-2015 [29, 30].
Population data were reported for the specific age groups
and years included in the model, so no further adjustments
were applied. Annual background deaths (supplementary
table S2 in appendix 1) were calculated by year
(1950–2030), gender and 5-year age groups based on rates
reported in two files (MORT/17-2 and MORT/17-3) from
the United Nations World Population Prospects 2017 data-
base [12]. Background rates were adjusted to account for
incrementally increased mortality related to CVD [31–33].
A standard mortality ratio 1.15 (uncertainty range
1.00–1.31) was applied to all background mortality rates
in all years of the model [31–33]. Incremental background
mortality rates are reported in table S3. Incremental CVD
mortality may increase with severity of liver disease and
vary by age group; however, data were largely unavailable
and a constant multiplier was applied. Progression to de-
compensated cirrhosis [34] and rates of liver-related deaths
among prevalent HCC, decompensated cirrhosis and liver
transplant cases [3, 24, 35, 36] were based on published es-
timates (table S1).
New NAFLD cases
The annual number of new cases was back-calculated for
each year based on the adult prevalence of obesity, for
which more robust data exist than those for NAFLD.
Trends for adult prevalence of obesity (BMI ≥30 kg/m2)
were used to estimate the annual number of new NAFLD
cases over time, with the fastest growth in prevalence oc-
curring simultaneously with the fastest increase in NAFLD
prevalence. All NAFLD cases were then tracked by fibro-
sis stage, with progression to advanced liver disease and
liver-related death (supplementary fig. S2 in appendix 1).
Relative changes in adult obesity were estimated using da-
ta reported from the Swiss National Health Survey [37, 38]
and the NCD Risk Factor Collaboration (NCD-RisC) es-
timates for Switzerland [7, 8, 39]. Variation between the
two sources for reported magnitude of obesity increase af-
ter 2015 were included as part of uncertainty analysis.
Figure 1: Model estimated cases by disease stage with 95% uncertainty interval – Switzerland 2015–2030. NAFLD = nonalcoholic fatty liver
disease.
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NAFLD prevalence
Among individuals ≥15 years of age in 2015, there was
an assumed NAFLD prevalence rate of 25% (uncertainty
range 20–30%). After adjustment for lower prevalence
among persons aged <15 years, prevalence among all ages
was estimated to be 21.6% in 2015. The age and gender
distribution of prevalent NAFLD cases was based on data
from general population studies where prevalence increas-
es with age and overall prevalence is higher among males
[40–42]. Prevalence among younger age groups not usual-
ly included in general population studies was assumed to
decline with decreasing age. Because of elevated mortali-
ty, it was assumed that prevalence would naturally decline
among the oldest age groups (≥80 years), with peak preva-
lence occurring in late middle age.
NASH status
NASH prevalence was calculated based on fibrosis pro-
gression among the total NAFLD population. NASH diag-
nosis is based on results of liver biopsy, which have serious
limitations in terms of reliably sampling and measuring
the features of NASH [43]. Furthermore, NASH-related fi-
brosis can regress in NAFLD patients [17]; the model in-
cluded an assumption that ≤5% of NAFLD cases without
NASH could be experiencing NASH regression, includ-
ing a portion with fibrotic changes. Because the features of
NASH have reduced, but fibrosis still remains, these cas-
es were classified as regressed NASH. Increasing fibrosis
stage was assumed to result in lower probability of expe-
riencing regressed NASH. Overall, a relatively small num-
ber of ≥F2 cases were classified as non-NASH NAFLD.
Fibrosis progression and NASH status were initially cal-
ibrated to surveillance data for NASH-related HCC [24],
with adjustments between countries based on relative rates
of overweight (BMI >25 and ≤30 kg/m2) and obesity [8]
and published odds of disease progression to advanced fi-
brosis [16]. A higher proportion of advanced fibrosis cases
results from increasing age of the overall population, and
timing of the obesity epidemic where large increases oc-
curred in earlier decades.
Liver transplants
Total annual liver transplants are reported by Swisstrans-
plant [44]. Using total annual transplant data, with expert
input for total transplants [45], we assumed that up to
20% of current liver transplants could be attributable to
NASH. These estimates were used to validate the model
outputs and informed by studies showing that a portion of
transplants indicated for cryptogenic or idiopathic cirrho-
sis are potentially related to NAFLD, based on high obe-
sity rates among the recipients [46, 47]. Given the uncer-
tainties around transplant demand and availability, it was
assumed that the annual number of NAFLD-related trans-
plants would remain constant until 2030. However, this
was a conservative estimate, as data already suggest that
the proportion of NAFLD-related transplants is increasing
[47].
Uncertainty and sensitivity analysis
Uncertainty analyses were conducted for the models. Beta-
PERT distributions [48] were defined for key model inputs,
including total NAFLD prevalence, excess background
mortality multipliers and fibrosis transition probabilities.
Monte Carlo simulation was conducted using Crystal Ball®
(11.1.3708.0 by Oracle®), an Excel® add-in, to estimate
95% uncertainty intervals. Sensitivity analyses were con-
ducted to identify the inputs that accounted for the greatest
variation in modelled outcomes.
Model validation
Surveillance data for liver cancer were used to validate the
results of the model. The National Institute for Cancer Epi-
demiology and Registration reports incident liver cancers
by 5-year period in Switzerland with 4035 total incident
liver cancers reported during 2010–2014 [49]. Assump-
tions were applied to these data for cancer under-report-
ing, cancer morphology and the proportion of cancers that
could be NAFLD-related. These assumptions were applied
to incident liver cancer data to develop a range for the
potential number of annual liver cancers attributable to
NAFLD. For under-reporting, it was conservatively as-
sumed that 10% of cancers may not be reported to the
registry with a range from 0 to 100% [50]. For cancer
morphology, an estimated 72% [51] of liver cancers were
assumed to be HCC, with a range of 65% [52] to 90%,
based on the Geneva Tumour Registry. The estimated pro-
portion of NAFLD-related HCC was 17% based on risk
factors for HCC surveillance at University Hospital of
Bern during 2010–2011 [53]. The conceivable range for
NAFLD-related HCC was estimated at 4% (low) [54] to
29% (high) [53]. This wide range was utilised owing to un-
certainty and changes over time in the aetiology of liver
cancer, with viral hepatitis expected to contribute relatively
fewer cases in the future. The outcomes of this analysis
for 1990–2014 were compared to model predicted incident
HCC (see fig. 3 below) to ensure that the model was pre-
dictive based on surveillance data for advanced disease.
Results
NAFLD population
Total prevalent NAFLD cases in 2018 were estimated to
be 1,898,000 (1,626,000–2,167,000) (22.2% [19.0–25.4%]
prevalence among all ages). By 2030, the total NAFLD
population was projected to increase 18% to 2,234,000
(1,914,000–2,550,000) cases (fig. 1), with overall preva-
lence rates estimated at 24.3% (20.827.7%). Likewise, F0/
F1 cases would increase 16% from 1,748,000
(1,451,600–2,053,000) to 2,028,000
(1,683,000–2,393,000) during 2018–2030. Even greater
relative increases were projected for later disease stages;
F2 cases would increase 35% during 2018–2030, from
79,700 (51,200–119,000) to 107,000 (69,000–159,000). F3
cases would increase from 47,100 (28,600–72,400) to
65,500 (39,700–101,000), a change of 40%. F4 (compen-
sated cirrhosis) cases would increase 40% from 21,100
(11,800–36,900) to 29,800 (16,700–52,100).
Prevalent NAFLD cases by age group and gender were
compared with the distribution of the non-NAFLD Swiss
population (fig. 2). Among modelled NAFLD cases in
2018, there were 15% more cases among males (1,015,000
cases as compared with 884,000 cases among females).
The age group with the largest number of NAFLD cases
was estimated to be the 50- to 54-year-old group with
224,400 cases in 2018 (fig. 2). By 2030, the largest preva-
lent NAFLD age group will be aged 60–64 years, with
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228,000 NAFLD cases. Overall NAFLD cases will number
1,204,000 among males, 17% greater than total female cas-
es (1,030,000 cases) (fig. 2).
The NAFL population was assumed to be cases with
steatosis only that never progressed to NASH, in addition
to a relatively small number of cases that were formerly
NASH and experienced disease regression. In 2018, the
NAFL population was estimated to be 1,444,000
(1,272,000–1,601,000) in Switzerland (76.1% of all
NAFLD cases) and will increase to 1,664,000
(1,469,000–1,835,000) cases in 2030 (74.5% of all
NAFLD cases), a 15% increase. NAFL classified as ≥F2
fibrosis were estimated at 710 cases in 2018, with a pro-
jected 960 cases in 2030.
NASH population
The number of NASH cases in 2018 was estimated to be
454,000 (356,000–566,000) in Switzerland, equivalent to
23.9% of all NAFLD cases. General population NASH
prevalence in 2018 was estimated to be 5.3% (4.2–6.6%).
In Switzerland, NASH cases were projected to increase
26% to 570,000 (446,000–714,000) cases in 2030 (see fig.
1), when they will comprise 25.5% of all NAFLD cases.
Overall prevalence of NASH in 2030 was estimated to be
6.2% (4.8–7.8%) (table 1).
Among NASH cases in 2018, 46,900 (28,500–72,200) and
21,000 (11,800–36,800) were classified as F3 and F4
(compensated cirrhosis), respectively. F3 cases encom-
passed approximately 10.4% of all NASH cases and 0.5%
(0.3–0.8%) of the total Swiss population (all ages), where-
as F4 cases accounted for 4.6% of all NASH cases and
0.2% (0.1–0.4%) of the total population. By 2030, the
numbers of F3 and F4 cases were both expected to increase
40% to 65,300 (39,600–100,000) cases and 29,700
(16,600–52,000) cases, respectively. In 2030, F3 cases
would account for 11.4% of all NASH cases whereas F4
cases would comprise 5.2% of the total NASH population.
Prevalence of NASH-related F3 was estimated to be 0.7%
(0.4–1.1%) in the total population in 2030, and F4 cases
were estimated at 0.3% (0.2–0.6%) of the total population.
NAFLD-related decompensated cirrhosis and HCC
In Switzerland, incident decompensated cirrhosis was pro-
jected to increase by 41%, from 720 (410–1300) cases in
Figure 2: Model age distribution of nonalcoholic fatty liver disease (NAFLD) and background population by sex and age group (thousands) –
Switzerland 2018 and 2030.
Table 1: Model estimates of NAFLD disease burden – Switzerland 2015–2030.
2015 2020 2025 2030
Prevalent
cases
NAFLD cases 1,792,000
(1,535,000–2,045,000)
1,964,000
(1,683,000–2,241,000)
2,108,000
(1,806,000–2,406,000)
2,234,000
(1,914,000–2,550,000)
NAFLD prevalence rate
(all ages)
21.5%
(18.4%–24.6%)
22.7%
(19.4%–25.8%)
23.5%
(20.2%–26.9%)
24.3%
(20.8%–27.7%)
F0 1,519,000
(1,286,000–1,749,000)
1,653,000
(1,400,000–1,906,000)
1,759,000
(1,490,000–2,031,000)
1,845,000
(1,564,000–2,132,000)
F1 135,000
(87,800–191,000)
152,000
(98,900–216,000)
168,000
(109,000–239,000)
183,000
(119,000–261,000)
F2 73,400
(47,200–110,000)
84,000
(54,000–126,000)
95,100
(61,300–142,000)
107,000
(69,000–159,000)
F3 43,300
(26,300–66,600)
49,700
(30,200–76,500)
57,000
(34,600–87,700)
65,500
(39,700–101,000)
Compensated cirrho-
sis
19,300
(10,800–33,700)
22,300
(12,500–38,900)
25,600
(14,300–44,700)
29,800
(16,700–52,100)
NASH cases 423,000
(332,000–528,000)
473,000
(371,000–592,000)
522,000
(408,000–653,000)
570,000
(446,000–714,000)
NASH prevalence rate (all
ages)
5.1%
(4.0%–6.3%)
5.5%
(4.3%–6.8%)
5.8%
(4.6%–7.3%)
6.2%
(4.8%–7.8%)
Incident
cases
Decompensated cirrhosis 660
(370–1,200)
760
(430–1,400)
870
(490–1,600)
1000
(570–1,900)
HCC 110
(70–170)
120
(80–200)
140
(90–220)
160
(100–260)
Liver death 530
(300–980)
610
(350–1,100)
700
(400–1,300)
820
(470–1,500)
HCC = hepatocellular carcinoma; NAFLD = nonalcoholic fatty liver disease; NASH = nonalcoholic steatohepatitis
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2018 to 1000 (580–1800) cases in 2030; cumulative inci-
dence during 2018–2030 was estimated to be 11,140 cases
(fig. 1). Incident HCC cases would increase by 39% dur-
ing 2018–2030 from 120 (70–180) to 160 (100–250) cases
(fig. 1). Cumulative incidence of HCC during 2018–2030
was estimated to be 1760 cases in Switzerland.
Mortality
In the total NASH population in Switzerland in 2018, there
were 9500 background deaths (including 1200 deaths clas-
sified as excess cardiovascular) and 580 (340–1000) liver-
related deaths. By 2030, annual liver-related deaths were
estimated to be 820 (480–1500) deaths in Switzerland
(40% increase from 2018) (fig. 1).
By 2030, it was projected that liver-related mortality will
comprise 2.8% of all deaths in the total NAFLD population
in Switzerland, as compared with 2.3% of deaths in 2018.
Liver deaths comprised 5.7% of liver-related deaths in the
entire NASH population in 2018, and will increase to 6.7%
of deaths in 2030. Cumulative liver deaths were estimated
to be 9000 deaths during 2018–2030.
Model estimates for HCC incidence during 1990–2014
were within the range expected based upon reported esti-
mates of liver cancer incidence, HCC morphology and the
proportion of HCCs that are potentially NAFLD-related.
Model NAFLD-related HCC incidence in 1990 comprised
8.0% of all incident HCC cases in Switzerland, increasing
to 16.2% of cases by 2014 (fig. 3).
There were 2192 total incident liver cancer cases during
1990–1994, increasing to 4035 by 2010–2014. After an es-
timated rate of incident liver cancer underreporting of 10%
was applied, annual incident liver cancers were estimat-
ed to be 482 cases annually during 1990–1994, increas-
ing to 888 cancers annually during 2010–2014. There are a
range of estimates for cancer morphology, but for the base
estimate, 72% of liver cancers were assumed to be HCC,
meaning that annual HCC cases increased from 347 during
1990–1994 to 639 annual cases by 2010–2014. Finally, a
wide range was considered for the proportion of HCC cas-
es that could be NAFLD related. These cases were estimat-
ed at 59 (14–101) cases during 1990–1994, increasing to
109 (26–185) cases during 2010–2014.
Figure 3: Predicted range of incident nonalcoholic fatty liver
(NAFLD)-related hepatocellular carcinoma (HCC), reported esti-
mates and model 95% uncertainty interval – Switzerland
1990–2014.
Discussion
Levels of liver disease in Switzerland are estimated to be
similar to those in other countries in Western Europe based
on rates of cirrhosis and liver-related mortality reported by
the European Association for the Study of the Liver HEPA-
HEALTH project [2]. The population of Switzerland is ag-
ing [12], resulting in potentially larger increases in disease
burden in the coming decades. Model results demonstrat-
ed that the burden of advanced disease among the NAFLD
population will increase in tandem with increases in av-
erage age and the ongoing increases in the obesity epi-
demic. Paediatric and adolescent populations experience
high rates of obesity in Switzerland [37] and are suscepti-
ble to developing NAFLD [55]. There may be an impact
of NAFLD in young populations with progression to ad-
vanced disease at earlier ages [56]. In the coming decade,
NASH will likely be a leading indication for liver trans-
plantation in Western Europe, as a result of a reduced bur-
den of viral hepatitis in combination with growing obesity
rates [10].
The current analysis utilised both literature review and ex-
pert interviews to design the model and validate model
outputs. For longitudinal trends in adult obesity levels,
estimates from the Swiss National Health Survey and
NCD-RisC study were used [7, 8, 38, 39]. In Switzerland,
it was assumed that an eventual plateauing of obesity
prevalence would result in a similar slowing in the growth
of the NAFLD epidemic. It was assumed that long-term
trends in NAFLD prevalence follow in tandem with trends
in adult obesity prevalence. However, more studies of
NAFLD prevalence in general populations should be con-
ducted in Switzerland. With the availability of more pub-
lished data, it will become possible to develop reliable
trends for NAFLD incidence and prevalence over longer
time periods. Likewise, a starting NAFLD prevalence of
25% among persons aged ≥15 years in 2015 represents
a most-likely case scenario for Switzerland, but high and
low prevalence estimates of 20–30% were used to capture
a potential range of prevalence, and to calculate 95% un-
certainty intervals for model outputs.
Studies of general European populations in multiple re-
gions have reported rates of advanced fibrosis based on
liver stiffness measurement (LSM) with transient elastog-
raphy that was not attributable to viral hepatitis or excess
alcohol consumption [13, 26, 27]. Over 5% of adults were
estimated to have LSM ≥8.0 kPa [27], and 0.6% of adults
aged ≥45 years were reported to have LSM ≥13.0 kPa
[13]. LSM cut-off values for determining fibrosis stage
vary between studies [57]. Results of the current analysis
are broadly consistent with estimates in general European
adult populations. As compared with results of NAFLD
modelling in the United States [25], Switzerland has a low-
er overall disease burden. The assumed base prevalence
was lower in the Switzerland model as compared with the
United States, and fibrosis progression was slower based
on reported odds for advanced fibrosis by BMI class [16].
These revisions to model inputs resulted in lower disease
burden. Such outcomes are consistent with reported data
showing higher levels of obesity and diabetes in the United
States [7, 58]; however, there is a need for further study of
NAFLD-related liver disease burden in Switzerland.
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Because of the long course of the disease, the burden of
NAFLD-related morbidity and mortality will increase for
decades, even if increases in obesity are halted; increased
age is a risk factor for advanced liver disease [16] and pro-
gression to advanced stages of NASH [14, 17]. The portion
of NASH among total NAFLD cases will increase, along
with the portion of NASH cases with advanced fibrosis.
Model results demonstrate a rapid increase in the number
of individuals with cirrhosis, which drives increases in de-
compensation and liver-related death, and the proportion of
HCC attributed to NAFLD is already reported to be grow-
ing rapidly [3, 59]. These outcomes will increase the de-
mand for NAFLD-related liver transplantation. The future
availability of donor organs and changes in other transplant
indicators, such as viral hepatitis, are unknown. However,
any increase in transplant demand incurs a high level of
disability [60] and economic costs [61]. In addition, liver
transplants may be limited as a treatment option among pa-
tients with multiple comorbidities. Model results empha-
sise the necessity of identifying NAFLD cases, especial-
ly persons with clinically significant fibrosis, who may be
candidates for therapy, before progression to advanced liv-
er disease.
A limitation of modelling is a scarcity of data from general
population studies measuring hepatic steatosis and fibrosis
with consistent methods [57]. Estimates rely on historical
data, and may not reflect the current disease burden owing
to ongoing increases in obesity and DM. Furthermore, as-
sumptions of the future growth in obesity are based on cur-
rent trends, which contributes to the uncertainty around fu-
ture disease burden. The analysis also does not consider
the potential impact of interventions to decrease the growth
in obesity and other risk factors for NAFLD, or of inter-
ventions focused on reducing the progression of disease
among populations at risk. The model adjusted for the in-
creasing prevalence of obesity, but there has been a dra-
matic increase in childhood obesity in recent decades [62],
possibly leading to a longer course of disease, on average,
with potentially a greater risk to develop end-stage liver
disease [16].
A lack of consistent diagnostic measures means that re-
ported NAFLD prevalence rates vary between studies [1],
and NASH can be histologically detected in some NAFLD
cases with normal liver enzyme levels [63]. Staging of fi-
brosis alone can be a predictor of long-term outcomes [64,
65]; however, there is considerable uncertainty around re-
ported fibrosis progression rates among studied NAFLD
and NASH populations [66]. This analysis stratified fibro-
sis progression by gender and two age groups, ages <40
years and ≥40 years (see table S1). Although male gen-
der and increased age are reported to result in faster pro-
gression, these differences have not been fully quantified
across the lifespan.
The results demonstrated a growing disease burden associ-
ated with NAFLD and NASH, following the trajectory of
increasing obesity in Switzerland [37]. Modelling has the
potential to inform healthcare systems. The World Health
Organization has called for increases in diabetes and obe-
sity to be stopped [67], with sustainable development goal
3.4 outlining a goal to reduce premature mortality from
noncommunicable diseases by one third before 2030.
There are increasing needs for strategies that address fac-
tors contributing to obesity, and identify and provide ther-
apeutic options for those with NAFLD [67] to avert further
increases in advanced liver disease and related mortality.
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